<DOC>
	<DOCNO>NCT02696265</DOCNO>
	<brief_summary>Objective : The purpose study compare efficacy safety complex fractionate atrial electrocardiogram ( CFAEs ) guide ablation pulmonary vein isolation base ablation patient persistent atrial fibrillation ( AF ) . Hypothesis : CFAE guide ablation increase atrial fibrillation free survival compare PVI guide ablation . Patient population : Patients persistent atrial fibrillation randomize base 2:1 ratio one two study arm : - CFAE guide ablation : CFAE map ablation AF aim restore sinus rhythm ablation , accord method Nademanee9 . PVI check ablation use map catheter - PVI guide ablation : wide antral pulmonary vein isolation map catheter control pulmonary vein signal</brief_summary>
	<brief_title>CFAEs Guided Ablation Versus PVI Persistent AF</brief_title>
	<detailed_description>Design : A prospective , multicenter , randomize unblinded clinical study . Objective : The purpose study compare efficacy safety complex fractionate atrial electrocardiogram ( CFAEs ) guide ablation pulmonary vein isolation base ablation patient persistent atrial fibrillation ( AF ) . Hypothesis : CFAE guide ablation increase atrial fibrillation free survival compare PVI guide ablation . Enrollment : 120 patient enrol study 2:1 CFAE v PVI group randomisation Clinical Sites : International ( include non EU-countries ) , Multicenter study . Patient population : Patients persistent atrial fibrillation ( define atrial fibrillation sustain beyond 7 day one year , last less 7 day necessitate pharmacologic electrical cardioversion , last long 48 hour ) document either 12-lead ECG , transtelephonic monitoring ( TTM ) , ambulatory holter monitoring ( HM ) telemetry strip physician 's note show continuous AF . Furthermore patient fail least one antiarrhythmic drug ( AAD ) ( Class I III ) evidence recurrent symptomatic AF intolerable side effect AAD . Eligible patient sign study inform consent form randomize base 2:1 ratio one two study arm : - CFAE guide ablation : CFAE map ablation AF aim restore sinus rhythm ablation , accord method Nademanee9 . PVI check ablation use map catheter - PVI guide ablation : wide antral pulmonary vein isolation map catheter control pulmonary vein signal Primary Endpoint : Freedom record atrial fibrillation atrial flutter atrial tachycardia recurrence ( &gt; 30 second ) without use AADs 18 month follow-up , post-blanking , either 12 lead ECG visit 24 hour holter monitoring symptom driven event monitoring . Additional risk : No additional risk anticipate patient enrol study compare patient undergo ablation symptomatic AF outside study , catheter use patient outside study , method ( PVI CFAE ) part daily practice . Although none report literature far , CFAE ablation may cause extensive lesion ablation persistent atrial fibrillation , especially posterior wall . This turn may cause pericardial effusion , myocardial rupture atrio-esophageal fistula . All potentially life threatening . However , energy setting change accord myocardial wall size pressure recording , order prevent complication . Furthermore , also group wide antral ablation , posterior wall target , possibly result event . For prevention posterior wall injury , temperature monitoring oesofagus may use . Thrombus formation complication occur ablation technique . Thrombi may dislodge embolize , cause stroke , myocardial infarction ischemic event . Therefore , require activate clotting time ( ACT ) keep 300 second . This monitor every 30 minute , heparin administer depend outcome . The operator responsible maintain adequate ACT . Radiation exposure fluoroscopic image catheter may result increase lifetime risk develop fatal malignancy ( 0.1 % ) genetic defect offspring ( 0.002 % ) . Potential Benefit : The direct benefit patient undergo ablation potential elimination AF episodes . It furthermore expect quality life improve less frequent hospitalization need . Whether morbidity cerebral vascular event prevent subject discussion . The information gain conduct study may benefit patient AF improve future treatment modality .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . Patients persistent atrial fibrillation , define atrial fibrillation : 1 . Sustained beyond 7 day one year . 2 . Or last less 7 day , long 48 hour necessitate pharmacologic electrical cardioversion . 2 . Documentation atrial fibrillation either 12lead ECG transtelephonic monitoring ( TTM ) , ambulatory holter monitor telemetry strip physician 's note show continuous AF . 3 . Failure least one antiarrhythmic drug ( AAD ) ( Class I III ) evidence recurrent symptomatic AF intolerable side effect AAD . 4 . Signed Patient Informed Consent Form . 5 . Age 18 year old . 6 . Able willing comply pre followup test requirement . 1 . Continuous AF &gt; 12 month ( 1Year ) ( Longstanding Persistent AF ) . 1 . Previous surgical catheter ablation atrial fibrillation . 2 . Any cardiac surgery within past 2 month ( 60 day ) ( include PCI ) . 3 . CABG surgery within past 6 month ( 180 day ) . 4 . Subjects ever undergo valvular cardiac surgical procedure ( ie , ventriculotomy , atriotomy , valve repair replacement presence prosthetic valve ) . 5 . Cardioversion refractory ( inability restore sinus rhythm 30 sec longer follow electrical cardioversion ) . 1 . If patient document evidence successfully cardioverted ( NSR &gt; 30 sec ) , patient must cardioverted prior ablation procedure study catheter . 2 . Failure cardiovert base criterion consider screen failure . 6 . Documented LA thrombus imaging . 7 . LA size &gt; 50 mm . 8 . LVEF &lt; 30 % . 9 . Contraindication anticoagulation ( heparin warfarin ) . 10 . History blood clot bleed abnormality . 11 . Myocardial infarction within past 2 month ( 60 day ) . 12 . Documented thromboembolic event ( include TIA ) within past 12 month ( 365 day ) . 13 . Rheumatic Heart Disease . 14 . Uncontrolled heart failure NYHA function class III IV . 15 . Awaiting cardiac transplantation cardiac surgery within next 12 month ( 365 day ) . 16 . Unstable angina . 17 . Acute illness active systemic infection sepsis . 18 . AF secondary electrolyte imbalance , thyroid disease , reversible noncardiac cause . 19 . Diagnosed atrial myxoma . 20 . Presence implant ICD . 21 . Significant severe pulmonary disease , ( eg , restrictive pulmonary disease , constrictive chronic obstructive pulmonary disease ) disease malfunction lungs respiratory system produce chronic symptom . 22 . Significant congenital anomaly medical problem opinion investigator would preclude enrollment study . 23 . Women pregnant ( evidenced pregnancy test pre menopausal ) . 24 . Enrollment investigational study evaluate another device , biologic , drug . 25 . Presence intramural thrombus , tumor abnormality precludes vascular access , manipulation catheter . 26 . Presence condition precludes vascular access . 27 . Life expectancy disease process likely limit survival le 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Complex fractionate atrial electrocardiogram</keyword>
	<keyword>pulmonary vein isolation</keyword>
	<keyword>ablation</keyword>
</DOC>